Comparable stake leader
GLAZER CAPITAL, LLC
SEC ownership of Esperion Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001434868.
Disclosed value leader
GLAZER CAPITAL, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Parsed ownership sources
-
13F and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GLAZER CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GLAZER CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001434868
- Issuer location
- Ann Arbor, MI
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Esperion Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GLAZER CAPITAL, LLC
Disclosed value leader
GLAZER CAPITAL, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
Lead comparable stake: 8.2%
13D/G row: GLAZER CAPITAL, LLC
Showing 1-8 of 50 holder rows.
Quick read
GLAZER CAPITAL, LLC leads the comparable SEC ownership view at 8.2%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GLAZER CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
GLAZER CAPITAL, LLC
8.2%
GOLDMAN SACHS GROUP INC
6.7%
VANGUARD CAPITAL MANAGEMENT LLC
5.1%
BB BIOTECH AG
4.9%
Two Seas Capital LP
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC |
13F
13D/G
Company
|
8.2%
from 13D/G
|
$70,836,000
22,416,339 shares
|
— | 30 Jun 2026 |
| GOLDMAN SACHS GROUP INC |
13D/G
13F
THE GOLDMAN SACHS GROUP, INC. · Company
|
6.7%
|
$54,938,678
17,222,156 shares
|
$0 | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.1%
|
$41,805,282
13,105,104 shares
|
$0 | 30 Jun 2026 |
| BB BIOTECH AG |
13D/G
|
4.9%
|
$8,821,598
9,694,064 shares
|
-$227,500 | 04 Mar 2025 |
| Two Seas Capital LP |
13D/G
|
4.7%
|
$25,836,769
9,749,724 shares
|
-$543,915 | 30 Sep 2025 |
| WASATCH ADVISORS LP |
13F
13D/G
Company
|
0.7%
from 13D/G
|
$6,099,385
1,930,185 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
8.6%
|
$69,924,547
22,128,021 shares
|
— | 30 Jun 2026 |
| Trium Capital LLP |
13F
Company
|
4.3%
|
$35,259,754
11,158,150 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$578,862.
Buys
$0
Insiders: 0
Sells
$578,862
Insiders: 3
Net
-$578,862
Shares: -178,930
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 178,930
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 76,185 | $0 | $240,364 | -$240,364 |
| 6-9 | 0 | 39,399 | $0 | $107,220 | -$107,220 |
| 9-12 | 0 | 63,346 | $0 | $231,278 | -$231,278 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to Esperion Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
BIOTECH TARGET N V
Net 12M change
-$578,862
Latest report
13 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BIOTECH TARGET N V | 10%+ Owner | $5,575,065 | Mixed | 24 May 2021 | ||
| Joanne M. Foody | Chief Medical Officer | $709,168 | Filing P/S | 17 Jul 2024 | ||
| Eric Warren | Chief Commercial Officer | $362,073 | Filing P/S | 17 Apr 2025 | ||
| Alan Fuhrman | Director | $132,602 | Mixed | 23 May 2024 | ||
| Antonio M. Jr. MD D. Phil Gotto | Director | $128,120 | Mixed | 23 May 2024 | ||
| Richard Bartram | Chief Financial Officer | $103,025 | Mixed | 14 Mar 2022 | ||
| Daniel Janney | Director | $59,777 | Mixed | 27 May 2021 | ||
| Stephen Rocamboli | Director | $55,408 | Mixed | 29 May 2025 | ||
| Mark E. Mcgovern | Director | $35,419 | Mixed | 27 May 2021 | ||
| J. Martin Carroll | Director | $0 | Mixed | 13 Jul 2026 | ||
| John Craig Thompson | Director | $0 | Mixed | 13 Jul 2026 | ||
| Robert E. Hoffman | Director | $0 | Mixed | 13 Jul 2026 | ||
| Seth H. Z. Fischer | Director | $0 | Mixed | 13 Jul 2026 | ||
| Sheldon L. Koenig | President and CEO, Director | $0 | -$415,817 | -100% | Mixed | 13 Jul 2026 |
| Jay Shepard | Director | $0 | Mixed | 13 Jul 2026 | ||
| John B. Harlow Jr. | Chief Commercial Officer | $0 | Mixed | 13 Jul 2026 | ||
| Benjamin Looker | Chief Legal Officer | $0 | -$84,774 | -100% | Mixed | 13 Jul 2026 |
| Benjamin Halladay | Chief Financial Officer | $0 | -$78,271 | -100% | Mixed | 13 Jul 2026 |
| Jeffrey Berkowitz | Director | Mixed | 26 May 2022 | |||
| Nicole Vitullo | Director | Mixed | 29 May 2025 |
Recent insider transactions for Esperion Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert E. Hoffman | ESPR | Common Stock | Disposed to Issuer | -100% | -85,153 | 0 | 13 Jul 2026 | Direct | ||
| Robert E. Hoffman | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -47,040 | 0 | 13 Jul 2026 | Direct | ||
| J. Martin Carroll | ESPR | Common Stock | Disposed to Issuer | -100% | -177,523 | 0 | 13 Jul 2026 | Direct | ||
| J. Martin Carroll | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -97,500 | 0 | 13 Jul 2026 | Direct | ||
| Jay Shepard | ESPR | Common Stock | Disposed to Issuer | -100% | -164,472 | 0 | 13 Jul 2026 | Direct | ||
| Jay Shepard | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -97,500 | 0 | 13 Jul 2026 | Direct | ||
| Seth H. Z. Fischer | ESPR | Common Stock | Disposed to Issuer | -100% | -141,023 | 0 | 13 Jul 2026 | Direct | ||
| Seth H. Z. Fischer | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -97,500 | 0 | 13 Jul 2026 | Direct | ||
| John Craig Thompson | ESPR | Common Stock | Disposed to Issuer | -100% | -79,873 | 0 | 13 Jul 2026 | Direct | ||
| John Craig Thompson | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -40,000 | 0 | 13 Jul 2026 | Direct | ||
| John B. Harlow Jr. | ESPR | Common Stock | Disposed to Issuer | -100% | -424,536 | 0 | 13 Jul 2026 | Direct | ||
| Benjamin Looker | ESPR | Common Stock | Disposed to Issuer | -100% | -667,524 | 0 | 13 Jul 2026 | Direct | ||
| Benjamin Looker | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -620,230 | 0 | 13 Jul 2026 | Direct | ||
| Benjamin Halladay | ESPR | Common Stock | Disposed to Issuer | -100% | -705,410 | 0 | 13 Jul 2026 | Direct | ||
| Benjamin Halladay | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -634,270 | 0 | 13 Jul 2026 | Direct | ||
| Sheldon L. Koenig | ESPR | Common Stock | Disposed to Issuer | -100% | -2,121,094 | 0 | 13 Jul 2026 | Direct | ||
| Sheldon L. Koenig | ESPR | Stock Option (right to buy) | Disposed to Issuer | -100% | -2,042,460 | 0 | 13 Jul 2026 | Direct | ||
| Benjamin Looker | ESPR | Common Stock | Sale | -1.74% | $37,305 | $3.16 | -11,824 | 667,524 | 17 Jun 2026 | Direct |
| Sheldon L. Koenig | ESPR | Common Stock | Sale | -2.47% | $169,070 | $3.16 | -53,588 | 2,119,111 | 17 Jun 2026 | Direct |
| Benjamin Halladay | ESPR | Common Stock | Sale | -1.51% | $33,989 | $3.16 | -10,773 | 702,829 | 17 Jun 2026 | Direct |
| John Craig Thompson | ESPR | Common Stock | Award | 79,873 | 79,873 | 28 May 2026 | Direct | |||
| Jay Shepard | ESPR | Common Stock | Award | 94.4% | 79,873 | 164,472 | 28 May 2026 | Direct | ||
| Robert E. Hoffman | ESPR | Common Stock | Award | 1512.8% | 79,873 | 85,153 | 28 May 2026 | Direct | ||
| Seth H. Z. Fischer | ESPR | Common Stock | Award | 130.6% | 79,873 | 141,023 | 28 May 2026 | Direct | ||
| J. Martin Carroll | ESPR | Common Stock | Award | 81.8% | 79,873 | 177,523 | 28 May 2026 | Direct | ||
| Benjamin Looker | ESPR | Common Stock | Sale | -0.83% | $15,429 | $2.70 | -5,708 | 679,348 | 17 Mar 2026 | Direct |
| Sheldon L. Koenig | ESPR | Common Stock | Sale | -1.16% | $69,547 | $2.72 | -25,578 | 2,172,699 | 17 Mar 2026 | Direct |
| Benjamin Halladay | ESPR | Common Stock | Sale | -0.89% | $17,377 | $2.70 | -6,424 | 713,602 | 17 Mar 2026 | Direct |
| Benjamin Looker | ESPR | Common Stock | Award | 78.3% | 300,840 | 685,056 | 13 Mar 2026 | Direct | ||
| Benjamin Looker | ESPR | Stock Option (right to buy) | Award | 269,230 | 269,230 | 13 Mar 2026 | Direct | |||
| Sheldon L. Koenig | ESPR | Common Stock | Award | 49.1% | 723,760 | 2,198,277 | 13 Mar 2026 | Direct | ||
| Sheldon L. Koenig | ESPR | Stock Option (right to buy) | Award | 647,460 | 647,460 | 13 Mar 2026 | Direct | |||
| Benjamin Halladay | ESPR | Common Stock | Award | 52.4% | 247,430 | 720,026 | 13 Mar 2026 | Direct | ||
| Benjamin Halladay | ESPR | Stock Option (right to buy) | Award | 221,270 | 221,270 | 13 Mar 2026 | Direct | |||
| Benjamin Looker | ESPR | Common Stock | Sale | -0.44% | $4,868 | $2.88 | -1,689 | 384,216 | 20 Jan 2026 | Direct |
| Sheldon L. Koenig | ESPR | Common Stock | Sale | -3.18% | $177,200 | $3.67 | -48,244 | 1,470,587 | 17 Dec 2025 | Direct |
| Benjamin Halladay | ESPR | Common Stock | Sale | -1.55% | $26,905 | $3.67 | -7,337 | 467,525 | 17 Dec 2025 | Direct |
| Benjamin Looker | ESPR | Common Stock | Sale | -1.66% | $23,898 | $3.67 | -6,517 | 385,905 | 17 Dec 2025 | Direct |
| John B. Harlow Jr. | ESPR | Common Stock | Award | 424,536 | 424,536 | 04 Dec 2025 | Direct | |||
| John B. Harlow Jr. | ESPR | Stock Option (right to buy) | Award | 380,000 | 380,000 | 04 Dec 2025 | Direct | |||
| Benjamin Looker | ESPR | Common Stock | Sale | -0.32% | $3,275 | $2.62 | -1,248 | 392,422 | 17 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.